Premium
Type 1 Induced Diabetes Abolishes Sex Differences in Proteinuria and Angiotensinogen Excretion in mRen2.Lewis Hypertensive Rats.
Author(s) -
Gilliam Shea,
Pirro Nancy,
Cohen Jonathan,
Chappell Mark,
Yamaleyeva Liliya
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.812.13
Subject(s) - endocrinology , medicine , proteinuria , blood pressure , streptozotocin , excretion , diabetes mellitus , creatinine , chemistry , renal function , kidney
The mRen2.Lewis strain exhibits sex differences such that males have higher blood pressure, proteinuria, and renal angiotensinogen (Aogen), as well as plasma and renal Ang II, but lower Ang‐(1–7). The present study examined whether these indices of cardiovascular disease remain in the adult mRen2 following induction of streptozotocin‐induced (STZ) diabetes at 15 weeks of age (65 mg/kg; single dose), and after ovariectomy (OVX, 11 weeks of age). In the STZ‐mRen2 after 4 weeks, proteinuria increased 8‐fold in males, but 20‐ and 30‐fold in intact and OVX females such that protein excretion was now similar among all groups. STZ increased Aogen excretion in males [3.5‐fold; 81 ± 13 to 292 ± 49 ng/mg creatinine], but to a greater extent in the intact [900‐fold; 0.3 ± 0.1 to 269 ± 109 ng/mg] and OVX females [200‐fold; 2.7 ± 0.7 to 475 ± 121 ng/mg]. Systolic blood pressures were not changed with STX in males [214 ± 6 vs. 218 ± 10 mmHg] or intact females [146 ± 6 vs. 164 ± 9 mmHg], but increased in the OVX group [162 ± 8 to 193 ± 3 mmHg]. However, plasma C‐reactive protein increased with STZ in intact [270 ±10 to 420 ± 17 μg/ml] and OVX females [216 ± 7 to 329 ± 18 μg/ml], but not males [246 ± 25 vs. 268 ± 14 μg/ml]. We conclude from these data that the renal protection afforded to the female mRen2 as compared to the males is abolished by STZ‐induced diabetes which may be independent of higher blood pressure. Funding: HL‐56973, HL‐51952.